BioPlus Acquisition Corp. (BIOSU) Prices Upsized $200M IPO

BioPlus Acquisition Corp. announced the pricing of its upsized $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “BIOSU” Friday, December 3.

The new SPAC intends to combine with a global life sciences business with strong preclinical or clinical data driving confidence in successful clinical proof of concept. BioPlus is led by Chairman and Chief Business Officer Jonathan Rigby, CEO and CFO Ross Haghighat, and Vice Chairman designee Ronald Eastman.

Total SPAC deal count for 2021 year-to-date is now 570. This offering is expected to close on Tuesday, December 7.

Cantor Fitzgerald & Co. is acting as the sole book running manager for the offering. Latham & Watkins LLP is serving as Issuer’s Counsel with  Ellenoff Grossman & Schole LLP serving as Underwriter’s Counsel. WithumSmith+Brown,PC serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.